NEW YORK (GenomeWeb News) – Axela today announced that it has acquired Xceed Molecular for an undisclosed sum.
The deal combined Axela's multiplex protein biomarker testing capabilities with Xceed's Ziplex System for gene expression analysis. Axela said that the new firm, which will operate under its name, will offer clinical researchers a portfolio of products for analysis of proteins, pathogens, DNA, and RNA to speed the validation and clinical application of biomarkers.
Axela CEO Rocky Ganske will serve in the same role for the newly combined firm, which will now be located at Xceed's headquarters in Toronto.
Ganske said the acquisition of Xceed "provides a tremendous opportunity to accelerate introduction of novel multiplex biomarkers for diagnostics. Our focus is to simplify multiplex assay development and validation with robust, easy-to-use tools for analysis of DNA, RNA, and protein biomarkers that are designed to move seamlessly from the clinical-research arena into the workflow of the clinical-diagnostics lab."
Xceed President and CEO David Deems will become president of Axela and oversee sales, marketing, and business development. Deems said in a statement that the complementary technologies are "well-positioned to improve diagnostics in infection, cancer, and other immune-related diseases."
The firms are introducing the new Axela at the 2010 American Association of Clinical Chemistry annual meeting, which is taking place this week in Anaheim, Calif.